Form 4: Bio-Techne Executive Reports Stock Transactions
Statement of Changes in Beneficial Ownership
Shane Bohnen, SVP - General Counsel of Bio-Techne Corp, reported significant stock transactions including the acquisition of 2,259 restricted stock units and the disposal of 740 shares.
Summary
- Shane Bohnen, SVP - General Counsel of Bio-Techne Corp, filed a Form 4 detailing changes in beneficial ownership of company stock.
- On April 3, 2026, Bohnen acquired 2,259 restricted stock units (RSUs) with a reported value of $0, indicating they were likely granted as compensation.
- On the same date, Bohnen disposed of 740 shares of common stock at a price of $53.13 per share.
- Following these transactions, Bohnen beneficially owns 6,644 shares of common stock directly.
- The filing also lists various stock options and performance restricted stock units with different vesting schedules and exercise prices, indicating ongoing equity-based compensation.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports routine equity transactions and compensation-related awards rather than significant strategic shifts or financial performance indicators.
Positives
- Acquisition of 2,259 restricted stock units, indicating continued equity-based compensation and potential future value.
- The disposal of 740 shares at $53.13 per share suggests a sale at a specific market price, potentially for personal liquidity needs.
Negatives
- Disposal of 740 shares of common stock, which could be interpreted as a reduction in direct ownership, although the context of RSUs suggests this is part of a compensation plan.
Risks
- The vesting of various stock options and RSUs is contingent on performance goals or specific future dates, introducing uncertainty regarding the ultimate realization of these equity awards.
- The Power of Attorney document indicates that Shane Bohnen is not assuming responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, which could lead to compliance issues if not properly managed by his appointed attorneys-in-fact.
Future Outlook
The filing details numerous stock options and restricted stock units with various vesting dates and performance conditions extending up to August 15, 2035, indicating a long-term equity incentive structure for management.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard for Section 16 officers and directors, providing transparency into insider stock transactions. Bio-Techne Corp operates in the biotechnology sector, where executive compensation often includes significant equity components tied to company performance and long-term value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Shane Bohnen has granted power of attorney to specific individuals to act on his behalf for filing Forms 3, 4, and 5 related to beneficial ownership of Bio-Techne Corporation securities. | 04/04/2023 | Ensures compliance with Section 16 reporting requirements even if Bohnen is unavailable, but places reliance on the appointed attorneys-in-fact. |
Stakeholder Impact
- Shareholders: Increased transparency into insider holdings and potential future dilution from equity awards vesting.
- Employees: The structure of equity awards for management can influence overall employee morale and retention strategies.
- Management: Direct impact on personal wealth through equity compensation and potential sale of shares.
Next Steps
- Continued vesting of stock options and RSUs according to their respective schedules and performance conditions.
- Potential future transactions by Shane Bohnen as outlined in the various equity awards.
Key Dates
| Date | Description |
|---|---|
| 04/03/2023 | Effective date of the Power of Attorney document. |
| 04/03/2026 | Transaction date for acquisition of 2,259 RSUs and disposal of 740 common stock shares. |
| 04/07/2026 | Date of signature for the Form 4 filing. |
Keywords
Form 4, SEC Filing, Bio-Techne Corp, TECH, Shane Bohnen, Stock Transaction, Beneficial Ownership, Restricted Stock Units, Stock Options, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.